Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13193MR)

This product GTTS-WQ13193MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hyperlipidemia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13193MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11842MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ477MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ10055MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ5569MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ3729MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ14862MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ10646MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW